Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
Qi S et al. | Significant prolongation of renal allograft survival by delayed combination therapy of FK778 with tacrolimus in nonhuman primates. | 2003 | Transplantation | pmid:12717189 |
Maruyama M et al. | Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. | 1990 | Transplantation | pmid:1696410 |
Sampaio MS et al. | Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. | 2012 | Transplantation | pmid:22129761 |
Garcia-Criado FJ et al. | Possible tacrolimus action mechanisms in its protector effects on ischemia-reperfusion injury. | 1998 | Transplantation | pmid:9798713 |
Mack-Shipman LR et al. | Reproductive hormones after pancreas transplantation. | 2000 | Transplantation | pmid:11063337 |
Suzuki S et al. | Pure red cell aplasia induced by FK506. | 1996 | Transplantation | pmid:8607191 |
Mourad G et al. | Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial. | 2017 | Transplantation | pmid:27547871 |
Atkison PR et al. | Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. | 1997 | Transplantation | pmid:9311719 |
Stevens RB et al. | A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. | 2015 | Transplantation | pmid:25083614 |
McDevitt-Potter LM et al. | A multicenter experience with generic tacrolimus conversion. | 2011 | Transplantation | pmid:21788920 |
Ravaioli M et al. | Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial. | 2015 | Transplantation | pmid:25757214 |
Krook H et al. | Immunosuppressive drugs in islet xenotransplantation: a tool for gaining further insights in the mechanisms of the rejection process. | 2002 | Transplantation | pmid:12438951 |
Blaheta RA et al. | Mycophenolate mofetil decreases endothelial prostaglandin E2 in response to allogeneic T cells or cytokines. | 2000 | Transplantation | pmid:10830246 |
Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
Ueki S et al. | Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. | 2006 | Transplantation | pmid:17198266 |
Sher LS et al. | Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. | 1997 | Transplantation | pmid:9256184 |
Younes BS et al. | The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. | 2000 | Transplantation | pmid:10919581 |
Cherikh WS et al. | A comparison of discharge immunosuppressive drug regimens in primary cadaveric kidney transplantation. | 2003 | Transplantation | pmid:12923430 |